Verastem, Inc. (VSTM)
7.965
-0.06
(-0.69%)
USD |
NASDAQ |
Sep 03, 16:00
7.965
0.00 (0.00%)
After-Hours: 17:35
Verastem Research and Development Expense (TTM) : 140.22M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 140.22M |
| March 31, 2026 | 123.67M |
| December 31, 2025 | 114.60M |
| September 30, 2025 | 103.74M |
| June 30, 2025 | 99.50M |
| March 31, 2025 | 92.78M |
| December 31, 2024 | 81.33M |
| September 30, 2024 | 83.02M |
| June 30, 2024 | 72.22M |
| March 31, 2024 | 67.05M |
| December 31, 2023 | 61.36M |
| September 30, 2023 | 49.59M |
| June 30, 2023 | 46.94M |
| March 31, 2023 | 48.93M |
| December 31, 2022 | 50.56M |
| September 30, 2022 | 51.21M |
| June 30, 2022 | 49.25M |
| March 31, 2022 | 44.09M |
| December 31, 2021 | 39.35M |
| September 30, 2021 | 38.10M |
| June 30, 2021 | 39.37M |
| March 31, 2021 | 38.99M |
| December 31, 2020 | 41.02M |
| September 30, 2020 | 43.32M |
| June 30, 2020 | 44.94M |
| Date | Value |
|---|---|
| March 31, 2020 | 46.94M |
| December 31, 2019 | 45.78M |
| September 30, 2019 | 42.08M |
| June 30, 2019 | 41.44M |
| March 31, 2019 | 42.47M |
| December 31, 2018 | 43.65M |
| September 30, 2018 | 46.14M |
| June 30, 2018 | 52.31M |
| March 31, 2018 | 48.97M |
| December 31, 2017 | 46.42M |
| September 30, 2017 | 42.06M |
| June 30, 2017 | 28.54M |
| March 31, 2017 | 23.98M |
| December 31, 2016 | 19.78M |
| September 30, 2016 | 20.58M |
| June 30, 2016 | 27.66M |
| March 31, 2016 | 34.22M |
| December 31, 2015 | 40.56M |
| September 30, 2015 | 42.56M |
| June 30, 2015 | 40.30M |
| March 31, 2015 | 37.56M |
| December 31, 2014 | 35.45M |
| September 30, 2014 | 33.56M |
| June 30, 2014 | 31.30M |
| March 31, 2014 | 29.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Dianthus Therapeutics, Inc. | 175.60M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |